BioNTech SE - ADR

NASDAQ:BNTX  
128.33
-1.67 (-1.28%)
Products

Pfizer And Biontech Submit Application To FDA For Emergency Use Authorization Of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

Published: 08/22/2022 14:42 GMT
BioNTech SE - ADR (BNTX) - Pfizer - Rolling Submission for Omicron Ba.
4/ba.
5-adapted Bivalent Vaccine to Be Completed With the European Medicines Agency in the Coming Days.
Pfizer and Biontech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.
4/ba.
5-adapted Bivalent Covid-19 Vaccine.
Further Company Coverage: [22uay.
De].
((reuters.
Briefs@thomsonreuters.
Com;)).